Cutaneous Oncology

Basal Cell Carcinoma

Treatment

1 BCC minimum, ≥ 1 cm

Advanced Disease

Concurrently on Vismodegib

SKIN0037
Phase II Open label, Single arm of Efficacy of Topical Remetinostat on Basal Cell Carcinoma
PI: Sarin Stanford

SKIN0031
Phase IIb Pembrolizumab for Unresectable or Metastatic Basal Cell Carcinoma
PI: Chang Stanford

SKIN0038
PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
PI: Chang Regeneron Pharmaceuticals

KEY

Pending
Open for Enrollment
Observational Study
Optional Path
Link
Trial Posting
Extension Study
Immunotherapy
Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu